Top

Published in:

01-06-2021 | Psoriatic Arthritis | Clinical Trials

Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial

Authors: Signe Holm Nielsen, Samra Sardar, Anne Sofie Siebuhr, Annette Schlemmer, Erik Berg Schmidt, Anne-Christine Bay-Jensen, Morten A. Karsdal, Jeppe Hagstrup Christensen, Salome Kristensen

Published in: Rheumatology International | Issue 6/2021

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by involvement of skin, axial and peripheral skeleton. An altered balance between extracellular matrix (ECM) formation and breakdown is a key event in PsA, and changes in ECM protein metabolites may provide insight to tissue changes. Dietary fish oils (n-3 PUFA) might affect the inflammation driven tissue turnover. The aim was to evaluate ECM metabolites in patients with PsA compared to healthy individuals and investigate the effects of n-3 PUFA. The 24-week randomized, double-blind, placebo-controlled trial of PUFA included 142 patients with PsA. Fifty-seven healthy individuals were included for comparison. This study is a sub-study investigating biomarkers of tissue remodelling as secondary outcomes. Serum samples at baseline and 24 weeks and healthy individuals were obtained, while a panel of ECM metabolites reflecting bone and soft tissue turnover were measured by ELISAs: PRO-C1, PRO-C3, PRO-C4, C1M, C3M, C4M, CTX-I and Osteocalcin (OC). C1M, PRO-C3, PRO-C4 and C4M was found to be elevated in PsA patients compared to the healthy individuals (from 56 to 792%, all p < 0.0001), where no differences were found for OC, CTX-I, PRO-C1 and C3M. PRO-C3 was increased by 7% in patients receiving n-3 PUFA after 24 weeks compared to baseline levels (p = 0.002). None of the other biomarkers was changed with n-3 PUFA treatment. This indicates that tissue turnover is increased in PsA patients compared to healthy individuals, while n-3 PUFA treatment for 24 weeks did not have an effect on tissue turnover. Trial registration NCT01818804. Registered 27 March 2013–Completed 18 February 2016. https://clinicaltrials.gov/ct2/show/NCT01818804?term=NCT01818804&rank=1

Mallbris L, Ritchlin CT, Ståhle M (2006) Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 8:355–363. https://doi.org/10.1007/s11926-006-0065-8CrossRefPubMed

Veale DJ, Fearon U (2018) The pathogenesis of psoriatic arthritis. Lancet 391:2273–2284. https://doi.org/10.1016/S0140-6736(18)30830-4CrossRefPubMed

Schett G, Coates LC, Ash ZR et al (2011) Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther. https://doi.org/10.1186/1478-6354-13-S1-S4CrossRefPubMedPubMedCentral

Bartosińska J, Michalak-Stoma A, Juszkiewicz-Borowiec M et al (2015) The assessment of selected bone and cartilage biomarkers in psoriatic patients from Poland. Mediators Inflamm. https://doi.org/10.1155/2015/194535CrossRefPubMedPubMedCentral

Karsdal MA, Nielsen MJ, Sand JM et al (2013) Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 11:70–92. https://doi.org/10.1089/adt.2012.474CrossRefPubMedPubMedCentral

Adair-Kirk TL, Senior RM (2008) Fragments of extracellular matrix as mediators of inflammation. Int J Biochem Cell Biol 40:1101–1110. https://doi.org/10.1016/j.biocel.2007.12.005CrossRefPubMed

Moz S, Aita A, Basso D et al (2017) Spondyloarthritis: matrix metalloproteinasesas biomarkers of pathogenesis and response to tumor necrosis factor (TNF) inhibitors. Int J Mol Sci 18:830. https://doi.org/10.3390/ijms18040830CrossRefPubMedCentral

Clore JN, Cohen IK, Diegelmann RF (1979) Quantitation of collagen types I and III during wound healing in rat skin. Proc Soc Exp Biol Med 161:337–340. https://doi.org/10.3181/00379727-161-40548CrossRefPubMed

Volk SW, Wang Y, Mauldin EA et al (2011) Diminished type III collagen promotes myofibroblast differentiation and increases scar deposition in cutaneous wound healing. Cells Tissues Organs 194:25–37. https://doi.org/10.1159/000322399CrossRefPubMedPubMedCentral

10.

Poschl E, Schotzer-Schrehardt U, Brachvogel B et al (2004) Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development. Development 131:1619–1628. https://doi.org/10.1242/dev.01037CrossRefPubMed

11.

Christgau S, Bitsch-Jensen O, Hanover Bjarnason N et al (2000) Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505–511. https://doi.org/10.1016/S8756-3282(00)00248-9CrossRefPubMed

12.

Baim S, Miller PD (2009) Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 24:561–574. https://doi.org/10.1359/jbmr.090203CrossRefPubMed

13.

Szulc P (2018) Bone turnover: Biology and assessment tools. Best Pract Res Clin Endocrinol Metab 32:725–738. https://doi.org/10.1016/j.beem.2018.05.003CrossRefPubMed

14.

Chavassieux P, Portero-Muzy N, Roux JP et al (2015) Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women? J Clin Endocrinol Metab 100:4662–4668. https://doi.org/10.1210/jc.2015-2957CrossRefPubMed

15.

Jadon DR, Nightingale AL, McHugh NJ et al (2015) Serum soluble bone turnover biomarkers in psoriatic arthritis and psoriatic spondyloarthropathy. J Rheumatol 42:21–30. https://doi.org/10.3899/jrheum.140223CrossRefPubMed

16.

D’Angelo S, Tramontano G, Gilio M et al (2017) Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol Res Rev 9:21–28. https://doi.org/10.2147/OARRR.S56073CrossRef

17.

Glintborg B, Ãstergaard M, Dreyer L et al (2011) Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 63:382–390. https://doi.org/10.1002/art.30117CrossRefPubMed

18.

Felquer MLA, Coates LC, Soriano ER et al (2014) Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol 41:2277–2285. https://doi.org/10.3899/jrheum.140876CrossRef

19.

Calder PC (2006) n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83:1505S-1519S. https://doi.org/10.1093/ajcn/83.6.1505SCrossRefPubMed

20.

Calder PC (2017) Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans 45:1105–1115. https://doi.org/10.1111/j.1365-2125.2012.04374.xCrossRefPubMed

21.

Veselinovic M, Vasiljevic D, Vucic V et al (2017) Clinical benefits of n-3 PUFA and ɤ-linolenic acid in patients with rheumatoid arthritis. Nutrients. https://doi.org/10.3390/nu9040325CrossRefPubMedPubMedCentral

22.

Gioxari A, Kaliora AC, Marantidou F, Panagiotakos DP (2018) Intake of ω-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a systematic review and meta-analysis. Nutrition 45:114-124.e4. https://doi.org/10.1016/j.nut.2017.06.023CrossRefPubMed

23.

De Caterina R (2011) N-3 fatty acids in cardiovascular disease. N Engl J Med 364:2439–2450. https://doi.org/10.1056/NEJMra1008153CrossRefPubMed

24.

Michael-Titus AT (2007) Omega-3 fatty acids and neurological injury. Prostaglandins Leukot Essent Fat Acids 77:295–300. https://doi.org/10.1016/j.plefa.2007.10.021CrossRef

25.

Decker MJ, Jones K, Keating GL et al (2016) Maternal dietary supplementation with omega-3 polyunsaturated fatty acids confers neuroprotection to the newborn against hypoxia-induced dopamine dysfunction. Sleep Sci 9:94–99. https://doi.org/10.1016/j.slsci.2016.05.007CrossRefPubMedPubMedCentral

26.

Devassy JG, Leng S, Gabbs M et al (2016) Omega-3 polyunsaturated fatty acids and oxylipins in neuroinflammation and management of Alzheimer’s disease. Adv Nutr 7:905–916. https://doi.org/10.3945/an.116.012187.ofCrossRefPubMedPubMedCentral

27.

Wann AKT, Mistry J, Blain EJ et al (2010) Eicosapentaenoic acid and docosahexaenoic acid reduce interleukin-1β-mediated cartilage degradation. Arthritis Res Ther. https://doi.org/10.1186/ar3183CrossRefPubMedPubMedCentral

28.

Knott L, Avery NC, Hollander AP, Tarlton JF (2011) Regulation of osteoarthritis by omega-3 (n-3) polyunsaturated fatty acids in a naturally occurring model of disease. Osteoarthr Cartil 19:1150–1157. https://doi.org/10.1016/j.joca.2011.06.005CrossRefPubMedCentral

29.

Kristensen S, Schmidt EB, Schlemmer A et al (2018) Beneficial effect of n-3 polyunsaturated fatty acids on inflammation and analgesic use in psoriatic arthritis: a randomized, double blind, placebo-controlled trial. Scand J Rheumatol 47:27–36. https://doi.org/10.1080/03009742.2017.1287304CrossRefPubMed

30.

Watkins BA, Li Y, Allen KG et al (2000) Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. J Nutr 130:2274–2284. https://doi.org/10.1016/j.jnutbio.2005.05.012CrossRefPubMed

31.

Watkins BA, Li Y, Lippman HE, Feng S (2003) Modulatory effect of omega-3 polyunsaturated fatty acids on osteoblast function and bone metabolism. Prostaglandins Leukot Essent Fat Acids 68:387–398. https://doi.org/10.1016/S0952-3278(03)00063-2CrossRef

32.

Yuan J, Akiyama M, Nakahama KI et al (2010) The effects of polyunsaturated fatty acids and their metabolites on osteoclastogenesis in vitro. Prostaglandins Other Lipid Mediat 92:85–90. https://doi.org/10.1016/j.prostaglandins.2010.04.001CrossRefPubMed

33.

Wauquier F, Léotoing L, Philippe C et al (2015) Pros and cons of fatty acids in bone biology. Prog Lipid Res 58:121–145. https://doi.org/10.1016/j.plipres.2015.03.001CrossRefPubMed

34.

Mangano KM, Sahni S, Kerstetter JE et al (2013) Polyunsaturated fatty acids and their relation with bone and muscle health in adults. Curr Osteoporos Rep 11:203–212. https://doi.org/10.1007/s11914-013-0149-0CrossRefPubMed

35.

Lau BYY, Cohen DJA, Ward WE, Ma DWL (2013) Investigating the role of polyunsaturated fatty acids in bone development using animal models. Molecules 18:14203–14227. https://doi.org/10.3390/molecules181114203CrossRefPubMedPubMedCentral

36.

Sharif PS, Asalforoush M, Ameri F et al (2010) The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial. Age (Omaha) 32:179–186. https://doi.org/10.1007/s11357-009-9122-3CrossRef

37.

Griel AE, Kris-Etherton PM, Hilpert KF et al (2007) An increase in dietary n-3 fatty acids decreases a marker of bone resorption in humans. Nutr J 6:4–11. https://doi.org/10.1186/1475-2891-6-2CrossRef

38.

Rajaram S, Yip EL, Reghunathan R et al (2017) Effect of altering dietary n-6: n-3 polyunsaturated fatty acid ratio with plant and marine-based supplement on biomarkers of bone turnover in healthy adults. Nutrients. https://doi.org/10.3390/nu9101162CrossRefPubMedPubMedCentral

39.

Damsgaard CT, Mølgaard C, Matthiessen J et al (2012) The effects of n-3 long-chain polyunsaturated fatty acids on bone formation and growth factors in adolescent boys. Pediatr Res 71:713–719. https://doi.org/10.1038/pr.2012.28CrossRefPubMed

40.

Serhan CN, Hong S, Gronert K et al (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196:1025–1037. https://doi.org/10.1084/jem.20020760CrossRefPubMedPubMedCentral

41.

Molfino A, Amabile MI, Monti M, Muscaritoli M (2017) Omega-3 polyunsaturated fatty acids in critical illness: anti-inflammatory, proresolving, or both? Oxid Med Cell Longev 2017:1–6. https://doi.org/10.1155/2017/5987082CrossRef

42.

Sundrarjun T, Komindr S, Archararit N et al (2004) Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-α and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis. J Int Med Res 32:443–454. https://doi.org/10.1177/147323000403200501CrossRefPubMed

43.

Sköldstam L, Börjesson O, Kjällman A et al (1992) Effect of six months of fish oil supplementation in stable rheumatoid arthritis. a double-blind, controlled study. Scand J Rheumatol 21:178–185. https://doi.org/10.3109/03009749209099218CrossRefPubMed

44.

Li K, Huang T, Zheng J et al (2014) Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor α: a meta-analysis. PLoS One. https://doi.org/10.1371/journal.pone.0088103CrossRefPubMedPubMedCentral

45.

Veale DJ, Torley HI, Richards IM et al (1994) A double-blind placebo controlled trial of efamol marine on skin and joint symptoms of psoriatic arthritis. Rheumatology 33:954–958. https://doi.org/10.1093/rheumatology/33.10.954CrossRef

46.

Madland TM, Björkkjaer T, Brunborg LA et al (2006) Subjective improvement in patients with psoriatic arthritis after short-term oral treatment with seal oil. A pilot study with double blind comparison to soy oil. J Rheumatol 33:307–310PubMed

47.

Lassus A, Dahlgren AL, Halpern MJ et al (1990) Effects of dietary supplementation with polyunsaturated ethyl ester lipids (Angiosan) in patients with psoriasis and psoriatic arthritis. J Int Med Res 18:68–73. https://doi.org/10.1177/030006059001800109CrossRefPubMed

48.

Akhyani M, Ehsani AH, Robati RM, Robati AM (2007) The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol 21:1330–1332. https://doi.org/10.1111/j.1468-3083.2007.02260.xCrossRefPubMed

49.

Frommer KW, Schäffler A, Rehart S et al (2015) Free fatty acids: potential proinflammatory mediators in rheumatic diseases. Ann Rheum Dis 74:303–310. https://doi.org/10.1136/annrheumdis-2013-203755CrossRefPubMed

50.

Brouwers H, Von Hegedus J, Toes R et al (2015) Lipid mediators of inflammation in rheumatoid arthritis and osteoarthritis. Best Pract Res Clin Rheumatol 29:741–755CrossRef

51.

Mysliwiec H, Harasim-Symbor E, Baran A et al (2019) Abnormal serum fatty acid profile in psoriatic arthritis. Arch Med Sci 15:1407–1414. https://doi.org/10.5114/aoms.2019.89451CrossRefPubMedPubMedCentral

52.

Goldberg RJ, Katz J (2007) A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 129:210–223. https://doi.org/10.1016/j.pain.2007.01.020CrossRefPubMed

53.

Kremer JM, Lawrence DA, Jubiz W et al (1990) Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clin Immunologic Eff Arthritis Rheum 33:810–820. https://doi.org/10.1002/art.1780330607CrossRef

Title: Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial
Authors: Signe Holm Nielsen
Samra Sardar
Anne Sofie Siebuhr
Annette Schlemmer
Erik Berg Schmidt
Anne-Christine Bay-Jensen
Morten A. Karsdal
Jeppe Hagstrup Christensen
Salome Kristensen
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keywords: Psoriatic Arthritis
Biomarkers
Published in: Rheumatology International / Issue 6/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-021-04861-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2021

Atypical presentation of immunoglobulin G4-related disease as subglottic stenosis: a case-based review

Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review

Acute liver injury as initial manifestation of systemic lupus erythematosus-induced myocarditis

IgG4-related disease with multiorgan involvement: a case-based review

Insulin resistance in patients with rheumatoid arthritis

Is exposure to environmental factors associated with a characteristic clinical and laboratory profile in systemic sclerosis? A retrospective analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page